XETRA · MRK.DE
Merck KGaA
€151.30+€1.00 (+0.67%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.53% below the high.
Loading market information…
SIX · CURN.SW · CHF
Stock price, earnings
Quote as of Oct 30, 2026, 11:50 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Curatis Holding AG’s quoted price sits in the lower half of its reported 52-week range, 38.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Curatis Holding AG’s next earnings report is currently expected on Apr 12, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Curatis Holding AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 03:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€151.30+€1.00 (+0.67%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.53% below the high.
$35.37+$0.12 (+0.34%)
Indivior Pharmaceuticals Inc’s quoted price sits in the upper half of its reported 52-week range, 17.38% below the high.
$6.71-$0.15 (-2.19%)
Regencell Bioscience Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 90.28% below the high.
CHF 4.47-CHF 0.11 (-2.44%)
Idorsia Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.87% below the high.
CHF 20.64-CHF 0.20 (-0.96%)
Kuros Biosciences AG’s quoted price sits in the lower half of its reported 52-week range, 36.45% below the high.
$3.18$0.00 (0.0%)
Esperion Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.83% below the high.
CHF 15.32-CHF 0.28 (-1.79%)
Santhera Pharmaceuticals Holding AG’s quoted price sits in the upper half of its reported 52-week range, 18.68% below the high.
CHF 9.00-CHF 0.13 (-1.42%)
Newron Pharmaceuticals S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 71.74% below the high.
